Global Technologies, Ltd.

Mr. Bruce  Brimacombe

Founder & Chairman

Mr. Fredirick  Cutcher

Chief Executive Officer, President, Chief Financial Officer, Secretary, Treasurer & Director

Global Technologies, Ltd., through its subsidiaries, engages in the online sale of CBD and hemp related products in the United States. The company operates a portal that provides access to live shopping, e-commerce, and product placement in brick and mortar retail outlets. It also offers sales and distribution, and third-party logistics services, as well as consulting services. Global Technologies, Ltd. was incorporated in 1999 and is based in Saint Petersburg, Florida.

This week saw significant movements in global markets driven by geopolitical tensions in the Middle East, robust U.S. job gains, and various economic indicators influencing investor sentiment across regions.

Global Markets Weekly: Oil Prices Rise Amid Middle East Tensions

Trade Desk remains a "buy" with a $123 price target, driven by growth in CTV, Retail Media, and innovations like UID2 and Kokai platform. Q2 FY24 earnings beat expectations with 26% YoY revenue growth and 34% YoY growth in earnings, as brands shift their spending towards premium inventory to drive precision targeting and higher ROAS. Expansion into smart TV OS and international markets offers significant growth opportunities despite a competitive landscape.

The Trade Desk: Global Domination Via CTV

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Guggenheim Global Healthcare Conference on Tuesday, November 12th, at the InterContinental Boston in Boston, MA. Biljana Naumovic, President, Solid Tumor, U.S. Oncology and Mark Wildgust, Vice President, Global Medical Affairs Oncology, will represent the Company in a session scheduled at 10:30 a.m. (Eastern Time). This live audio webcast will be available to investors and other interested parties by.

Johnson & Johnson to Participate in the Guggenheim Global Healthcare Conference

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that it presented data showing the effectiveness of sebetralstat in reducing anxiety among people experiencing hereditary angioedema (HAE) attacks at the HAEi Global Angioedema Forum (GAF) taking place in Copenhagen, Denmark, October 4 - 5, 2024. These data were generated in the KONFIDENT phase 3 clinical trial, for which the Company disclosed top line results in February 2024.

KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum

Global Ship Lease Inc Company Update & Container Shipping Sector {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"GuruFocus.com","item":"https://www.gurufocus.com"},{"@type":"ListItem","position":2,"name":"Latest News","item":"https://www.gurufocus.com/latest-news"},{"@type":"ListItem","position":3,"name":"All","item":"https://www.gurufocus.com/latest-news/all"},{"@type":"ListItem","position":4,"name":"Business Services","item":"https://www.gurufocus.com/latest-news/all/business-services"},{"@type":"ListItem","position":5,"name":"GSL","item":"https://www.gurufocus.

Global Technologies, Ltd.GTLL

Global Technologies, Ltd.
GTLL